Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 The European Vitamins ... Europe with analysis and projection of revenue. The market ... million in 2012 to $1,202.08 million by 2018, at ... Browse through the TOC of the European Vitamins Market ... provided. This also provides a glimpse of the segmentation ...
(Date:7/23/2014)... European Bio fertilizers Market Report defines and segments the ... of revenue. The bio fertilizers market in Europe is ... 2012 to $4,582.2 million by 2017, at a CAGR ... the TOC of the European Bio fertilizers Market report, ... , http://www.micromarketmonitor.com/market/europe-bio-fertilizer-4637178345.html , The bio fertilizers ...
(Date:7/23/2014)... (July 23, 2014) Statins, a class of drugs ... patient,s risk of developing Barrett,s esophagus, according to a ... , the official journal of the American Gastroenterological Association. ... with statin use. , "Patients who received statins had ... Barrett,s esophagus compared to non-users," said study author Hashem ...
(Date:7/23/2014)... to a new market research report of "Semiconductor (Silicon) ... IP), Design Architecture (Hard IP, Soft IP), Processor Type ... & Analysis to 2013 - 2020", the semiconductor (silicon) ... of 12.6% from 2014 to 2020 and reach $5.63 ... data tables with 60 figures spread through 337 pages ...
(Date:7/23/2014)... identified three genetic changes linked to an increased risk ... investigators, was published online July 20 in Nature ... the most common malignancies among women worldwide, most studies ... focused on women of European ancestry. , Given the ... Asian women and those of European ancestry, the investigators ...
Breaking Medicine News(10 mins):Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 2Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 3Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 4Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2
... has found that alcohol does not kill off brain ... Queensland Brain Institute director Professor Perry Bartlett, the notion ... function similar to a napalm bomb strike, is erroneous. ... the world's top neuroscientists, claims that there is no ...
... Anderson Cancer Center have found in pre-clinical trials that ... in pancreatic cancer that shrinks or eradicates tumours, inhibits ... ,"This vehicle, or vector, is so targeted and ... used for therapy and perhaps for imaging," notes senior ...
... Residents in the United Kingdom would have to consider ... want to enjoy a pollution-free and greener future, a ... has said. ,According to the report, the ... operated cars and avoiding affordable flights. ...
... stroke patients practise daily tasks with impaired limbs, are ... Administration has approved a new robotic device called the Myomo ... arms. It is to hit the market shortly. ... weak electrical activity in patients arm muscles and providing just ...
... a new gene mutation that is associated with frontotemporal ... known as Prick's disease . ,Frontotemporal ... brain that control behaviour and language. Language problems, personality ... ,Unlike Alzheimer's disease, this Frontotemporal dementia does ...
... many of the genetic bits and pieces that drive ... disadvantages to humans or other animals. ,Nicholas ... Medicine said that the Hopkins experiments demonstrate that one ... DNA repeat elements that make up over 40 percent ...
Cached Medicine News:Health News:Gene Therapy Eradicates Pancreatic Cancer in Mice 2Health News:Brits Need to Change Lifestyle to Have a Greener Future: Report 2Health News:FDA Approve S Robotic Device to Help Stroke Patients 2Health News:FDA Approve S Robotic Device to Help Stroke Patients 3Health News:FDA Approve S Robotic Device to Help Stroke Patients 4Health News:Scientists Identify New Genetic Mutation Behind Common Dementia 2Health News:Completely Neutral Evolutionary Changes Helped Shape Our Genome 2
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... July 23, 2014  RT Oncology Services Corporation today ... join its board of directors. Mr. Mundie is currently ... he works on strategic projects within the company and ... chief research and strategy officer. ... RainTree, said, "Craig is a visionary technology executive. His ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies ... market entry results in $5.4 billion in lost savings ... by economic consulting firm Matrix Global Advisors ... Required by the Food and Drug Administration ... are intended to improve drug safety by ensuring that ...
Breaking Medicine Technology:Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
Medicine Products: